Compare JMIA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | PHAR |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | Germany | Netherlands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 1.0B |
| IPO Year | 2018 | 2020 |
| Metric | JMIA | PHAR |
|---|---|---|
| Price | $6.82 | $13.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $16.75 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.6M | 5.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.18 | $10.04 |
| Revenue Next Year | $23.26 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $9.54 |
| 52 Week High | $14.72 | $21.34 |
| Indicator | JMIA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 46.14 |
| Support Level | $6.45 | $12.88 |
| Resistance Level | $7.59 | $13.61 |
| Average True Range (ATR) | 0.35 | 0.54 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 52.26 | 20.32 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.